These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20922209)

  • 1. Emergence of Crohn's disease in juvenile idiopathic arthritis during treatment with etanercept: a causal link or a mere coincidence?
    Oikonomou KA; Kapsoritakis AN; Tsiopoulos FD; Tsikouras AN; Potamianos S
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):342. PubMed ID: 20922209
    [No Abstract]   [Full Text] [Related]  

  • 2. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature.
    Wiegering V; Morbach H; Dick A; Girschick HJ
    Rheumatol Int; 2010 Apr; 30(6):801-4. PubMed ID: 19506877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crohn's disease in a patient with juvenile idiopathic arthritis after starting etanercept therapy - causal link or only temporal coincidence?
    Flemming GM; Tóth G; Gebauer C; Schuster V
    Klin Padiatr; 2013 Nov; 225(6):350-1. PubMed ID: 24166091
    [No Abstract]   [Full Text] [Related]  

  • 4. Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis.
    Prince FH; van Suijlekom-Smit LW
    Rheumatol Int; 2008 Feb; 28(4):397-8, author reply 399. PubMed ID: 17940772
    [No Abstract]   [Full Text] [Related]  

  • 5. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Sandborn WJ; Hanauer SB; Katz S; Safdi M; Wolf DG; Baerg RD; Tremaine WJ; Johnson T; Diehl NN; Zinsmeister AR
    Gastroenterology; 2001 Nov; 121(5):1088-94. PubMed ID: 11677200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alopecia areata in a patient with psoriatic arthritis and Crohn's disease receiving etanercept.
    Costa L; Atteno M; Caso F; Scarpato L; Del Puente A; Scarpa R
    Int J Rheum Dis; 2014 Feb; 17(2):219-20. PubMed ID: 24576280
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunomodulatory effects of etanercept (TNFR:Fc) and its use in a patient with Crohn's disease.
    Srivastava MD
    Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):125-41. PubMed ID: 11458980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Crohn's disease in a patient taking etanercept.
    Oh J; Arkfeld DG; Horwitz DA
    J Rheumatol; 2005 Apr; 32(4):752-3. PubMed ID: 15801037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optic neuritis associated with etanercept therapy for juvenile arthritis.
    Tauber T; Turetz J; Barash J; Avni I; Morad Y
    J AAPOS; 2006 Feb; 10(1):26-9. PubMed ID: 16527676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis.
    Ruemmele FM; Prieur AM; Talbotec C; Goulet O; Schmitz J
    J Pediatr Gastroenterol Nutr; 2004 Aug; 39(2):203-6. PubMed ID: 15269630
    [No Abstract]   [Full Text] [Related]  

  • 14. Etanercept and urticaria in patients with juvenile idiopathic arthritis.
    Skyttä E; Pohjankoski H; Savolainen A
    Clin Exp Rheumatol; 2000; 18(4):533-4. PubMed ID: 10949736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis.
    Dekker L; Armbrust W; Rademaker CM; Prakken B; Kuis W; Wulffraat NM
    Clin Exp Rheumatol; 2004; 22(2):252-8. PubMed ID: 15083897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept for Crohn's disease.
    Travers SB
    N Engl J Med; 2004 Feb; 350(8):840; author reply 840. PubMed ID: 14973205
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis.
    Lepore L; Marchetti F; Facchini S; Leone V; Ventura A
    Clin Exp Rheumatol; 2003; 21(2):276-7. PubMed ID: 12747299
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis.
    Foeldvari I; Krüger E; Schneider T
    Ann Rheum Dis; 2003 Sep; 62(9):908-9. PubMed ID: 12922972
    [No Abstract]   [Full Text] [Related]  

  • 19. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
    Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
    JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S23-9. PubMed ID: 11380040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.